What are the key intermediates in abrocitinib manufacturing?
The manufacturing process for abrocitinib involves several key intermediates. One notable intermediate is a pyrimidine derivative, [1] specifically a compound formed through a multi-step synthesis that includes a palladium-catalyzed Suzuki coupling reaction. Another crucial intermediate is a substituted piperidine derivative, [1] which is synthesized via reactions such as reduction and nucleophilic substitution.
How is the synthesis of abrocitinib protected by patents?
The synthesis of abrocitinib, including its intermediates and the final compound, is protected by various patents. For example, patents have been granted for specific synthetic routes and novel intermediates used in the production of abrocitinib. [1] These patents aim to prevent generic manufacturers from using similar or identical processes to produce the drug. DrugPatentWatch.com provides detailed information on the patent landscape for abrocitinib, including patent filings and their status. [2]
When does the patent protection for abrocitinib expire?
Patent expiration dates are critical for understanding when generic versions of abrocitinib could become available. Information regarding the specific patent expiration timelines for abrocitinib can be found through resources like DrugPatentWatch.com, which tracks patent lifecycles for pharmaceutical products. [2] Generally, patent protection for a drug can involve multiple patents covering different aspects, such as the compound itself, its use, and its manufacturing process.
Are there alternative manufacturing routes for abrocitinib?
While specific patented routes exist for abrocitinib, research and development into alternative synthetic pathways are common in the pharmaceutical industry. These efforts often aim to improve efficiency, reduce costs, or circumvent existing patents. However, any new route would still need to comply with regulatory standards and may be subject to its own patent protections.
What are the regulatory considerations for abrocitinib manufacturing?
The manufacturing of abrocitinib, like all pharmaceuticals, is subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the quality, safety, and efficacy of the drug. This includes rigorous control over the synthesis of intermediates and the final active pharmaceutical ingredient (API).
Who are the main competitors for abrocitinib?
Abrocitinib is a Janus kinase (JAK) inhibitor used to treat atopic dermatitis. Its main competitors are other JAK inhibitors and biologic medications approved for similar indications. These include drugs like upadacitinib, ruxolitinib, and dupilumab, which target different pathways but are used to manage moderate to severe atopic dermatitis. [3]
---
Sources:
[1] https://patents.google.com/patent/WO2019178115A1/en
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483487/